// you’re reading...

General Biotechnology

Is ImClone Out of the Woods?

By Yali ⋅ January 28, 2004 ⋅ Email This Post Email This Post ⋅ Print This Post Print This Post ⋅ Post a comment

Is ImClone Out of the Woods?
If the FDA approves its Erbitux anticancer treatment, as S&P expects, the biotech’s volatile stock should be set for solid growth

Print This Post

Discussion

No comments for “Is ImClone Out of the Woods?”

Post a comment

Building Biotechnology - Starting, Managing, and Understanding Biotechnology Companies   The Business of Biotechnology - Profit From the Growing Influence of Biotechnology
Best Practices in Biotechnology Business Development Best Practices in Biotechnology Education
Journal of Commercial Biotechnology 
DrugPatentWatch.com